Target immobilization as a strategy for NMR-based fragment screening: Comparison of TINS, STD, and SPR for fragment hit identification

Journal of Biomolecular Screening

Volumn 15, Issue 8, 2010, Pages 978-989

  Kobayashi, Masakazu ^a   Retra, Kim ^b   Figaroa, Francis ^a   Hollander, Johan G ^a   Ab, Eiso ^a   Heetebrij, Robert J ^a   Irth, Hubertus ^b   Siegal, Gregg ^a,c  

^a ZoBio   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

fragment based drug discovery; NMR; saturation transfer difference NMR; surface plasmon resonance; TINS

Indexed keywords

LIGAND;

ARTICLE; BINDING AFFINITY; BIOSENSOR; COMPARATIVE STUDY; CONTROLLED STUDY; FRAGMENTATION REACTION; HIGH THROUGHPUT SCREENING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SATURATION TRANSFER DIFFERENCE; SCREENING; SPECTROSCOPY; SURFACE PLASMON RESONANCE; TARGET IMMOBILIZED NUCLEAR MAGNETIC RESONANCE SCREENING;

BIOSENSING TECHNIQUES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; IMMOBILIZED PROTEINS; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE;

EID: 78449307474     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057110375614     Document Type: Article

References (29)

1. Hann MM, Leach AR, Harper G.: Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inform Comp Sci 2001 ; 41: 856-864.
2. Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000 ; 44: 235-249.
3. Fink T., Reymond JL: Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 2007 ; 47: 342-353.
4. Hopkins AL, Groom CR, Alex A.: Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004 ; 9: 430-431.
5. Keseru GM, Makara GM: The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009 ; 8: 203-212.
6. Howard S., Berdini V., Boulstridge JA, Carr MG, Cross DM, Curry J.,, et al. Fragment-based discovery of the Pyrazol-4-yl Urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J Med Chem 2009 ; 52: 379-388.
7. Hartshorn MJ, Murray CW, Cleasby A., Frederickson M., Tickle IJ, Jhoti H.: Fragment-based lead discovery using X-ray crystallography. J Med Chem 2005 ; 48: 403-413.
8. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996 ; 274: 1531-1534.
9. Hamalainen MD, Zhukov A., Ivarsson M., Fex T., Gottfries J., Karlsson R.,, et al. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. J Biomol Screen 2008 ; 13: 202-209.
10. Barker J., Courtney S., Hesterkamp T., Ullmann D., Whittaker M.: Fragment screening by biochemical assay. Exp Opin Drug Discov 2006 ; 1: 225-236.
11. Mayer M., Meyer B.: Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 1999 ; 38: 1784-1788.
12. Dalvit C., Fagerness PE, Hadden DTA, Sarver RW, Stockman BJ: Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. J Am Chem Soc 2003 ; 125: 7696-7703.
13. Vanwetswinkel S., Heetebrij RJ, van Duynhoven J., Hollander JG, Filippov DV, Hajduk PJ,, et al. TINS, target immobilized NMR screening: an efficient and sensitive method for ligand discovery. Chem Biol 2005 ; 12: 207-216.
14. Marquardsen T., Hofmann M., Hollander JG, Loch CMP, Kiihne SR, Engelke F.,, et al. Development of a dual cell, flow-injection sample holder, and NMR probe for comparative ligand-binding studies. J Magn Reson 2006 ; 182: 55-65.
15. Antonysamy SS, Aubol B., Blaney J., Browner MF, Giannetti AM, Harris SF,, et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg Med Chem Lett 2008 ; 18: 2990-2995.
16. Siegal G., Ab E., Schultz J.: Integration of fragment screening and library design. Drug Discov Today 2007 ; 12: 1032-1039.
17. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
18. Murali N., Miller WM, John BK, Avizonis DA, Smallcombe SH: Spectral unraveling by space-selective Hadamard spectroscopy. J Magn Reson 2006 ; 179: 182-189.
19. Hajduk PJ, Huth JR, Fesik SW: Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005 ; 48: 2518-2525.
20. Maurer T.: NMR studies of protein-ligand interactions. Methods Mol Biol 2005 ; 305: 197-213.
21. Boehm HJ, Boehringer M., Bur D., Gmuender H., Huber W., Klaus W.,, et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization: a promising alternative to random screening. J Med Chem 2000 ; 43: 2664-2674.
22. Card GL, Blasdel L., England BP, Zhang C., Suzuki Y., Gillette S.,, et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 2005 ; 23: 201-207.
23. Maly DJ, Choong IC, Ellman JA: Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci U S A 2000 ; 97: 2419-2424.
24. Wells JA, McClendon CL: Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007 ; 450: 1001-1009.
25. Dalvit C., Fogliatto G., Stewart A., Veronesi M., Stockman BJ: WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR 2001 ; 21: 349-359.
26. Früh V., Heetebrij RJ, Siegal G.: Target immobilized NMR screening: validation and extension to membrane proteins. In Zartler ER, Shapiro MJ (eds): Fragment-Based Drug Discovery. New York: John Wiley, 2008: 135-158.
27. Siegal G., Hollander JG: Target Immobilization and NMR screening of fragments in early drug discovery. Curr Top Med Chem 2009 ; 9: 1736-1745.
28. McGovern SL, Caselli E., Grigorieff N., Shoichet BK: Aggregation: a common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 2002 ; 45: 1712-1722.
29. Dalvit C.: NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today 2009 ; 14: 1051-1057.